Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
1.
Clin Chim Acta ; 521: 278-284, 2021 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-34331951

RESUMEN

BACKGROUND: Presepsin is a diagnostic and prognostic biomarker of both bacterial infection and sepsis; however, elevated presepsin levels have also been observed without sepsis. We conducted several analyses to evaluate the clinical laboratory parameters affecting presepsin levels. METHOD: We analyzed the association between sequential organ failure assessment (SOFA) scores and plasma presepsin levels and then analyzed clinical laboratory parameters in 567 patients with univariate and multivariate regression analysis and analysis of covariance (ANCOVA). We also determined presepsin in the bile of 11 patients and examined the presepsin immunostaining in liver. RESULTS: Spearman's rank correlation analysis with loge change revealed that presepsin levels were closely associated with loge-transformed SOFA score (ρ = 0.541), alkaline phosphatase (ALP); (ρ = 0.454) and gamma-glutamyl transferase; (ρ = 0.505). Multivariate regression analysis revealed that loge-transformed SOFA score (ß-coefficient = 0.316), ALP level (ß-coefficient = 0.380), and creatinine level (ß-coefficient = 0.290) independently and significantly affected loge presepsin levels. ANCOVA revealed that presepsin levels were significantly higher in patients with hepatobiliary disease. Patients who presented with dilatation of the bile ducts and elevated ALP levels or total bilirubin levels exhibited high presepsin levels in the bile. Presepsin production in liver Kupffer cells was also confirmed by immunostaining. CONCLUSION: Presepsin levels is correlated with the elevation of biliary enzymes in patients without renal dysfunction or sepsis. Additionally, presepsin exists with high concentrations in the bile and is positive in Kupffer cells.


Asunto(s)
Enfermedades de las Vías Biliares , Sepsis , Bilis , Enfermedades de las Vías Biliares/diagnóstico , Biomarcadores , Humanos , Receptores de Lipopolisacáridos , Fragmentos de Péptidos , Estudios Retrospectivos , Sepsis/diagnóstico
2.
Mod Rheumatol Case Rep ; 5(2): 437-441, 2021 07.
Artículo en Inglés | MEDLINE | ID: mdl-33847235

RESUMEN

Rapidly destructive coxopathy (RDC) is a disease that is sometimes seen in geriatric patients. A total hip arthroplasty (THA) is mostly chosen to treat the RDC, but few cases are known that received THAs due to RDC associated with dialysis amyloidosis. We report a case of RDC due to dialysis amyloidosis with special references to its pathophysiology. The case involved a 61-year-old male who had been on dialysis for seven years due to diabetic nephropathy. At his first visit, the radiographs showed collapse and flattening of the femoral head, which progressed within a month. Magnetic resonance imaging for the hip disclosed bone marrow edoema of the acetabulum and sclerosis of the subchondral bone of the femoral head. Biochemical analyses for the blood revealed high inflammatory reactions with elevated C-reactive protein and white blood cell count, but the joint fluid cultures were negative for general bacteria, tubercle bacillus, and nontuberculous mycobacteria. As he did not have gastrointestinal disorders or inflammatory arthritis other than the left hip and no disease that caused elevated inflammatory reactions was observed, we diagnosed the patient with RDC due to dialysis amyloidosis, and a THA was performed. Pathological findings for the synovium collected during surgery showed infiltration of the inflammatory mononuclear cells and vascular hyperplasia. The synovial tissues were extensively stained with an antibody to ß2-microglobulin. Many tartrate-resistant acid phosphatase-positive multinucleated cells were also observed in the synovium. One year after surgery, his left hip pain disappeared and he returned to work.


Asunto(s)
Amiloidosis , Enfermedades Óseas , Diálisis Renal , Amiloidosis/complicaciones , Amiloidosis/etiología , Artroplastia de Reemplazo de Cadera , Enfermedades Óseas/diagnóstico , Enfermedades Óseas/cirugía , Nefropatías Diabéticas/terapia , Cabeza Femoral/patología , Humanos , Masculino , Persona de Mediana Edad , Diálisis Renal/efectos adversos
3.
Biochem Biophys Res Commun ; 516(3): 693-698, 2019 08 27.
Artículo en Inglés | MEDLINE | ID: mdl-31253396

RESUMEN

Triple-negative breast cancer (TNBC) is associated with poor prognosis, because of no effective targeted therapy. In the present study, we demonstrated the crucial role of the aryl hydrocarbon receptor (AhR) in mediating the effects of the chemotherapeutic agent doxorubicin (DOX) in the chemotherapeutic sensitivity of TNBC. Firstly, we established AhR knockout (KO) MDA-MB 231 TNBC cells. The cytotoxic effects of DOX were more pronounced in AhR KO cells than in parental cells. In addition, our results indicated that AhR KO cells showed downregulated expression of DOX-metabolism enzyme, aldo-keto reductase (AKR) 1C3, relative to those of parental cells. Furthermore, AhR was found to enhance AKR1C3 promoter reporter activity, suggesting that AKR1C3 mRNA transcription is activated by AhR. Additionally, our findings confirmed that the downregulation of AKR1C3 expression enhanced DOX sensitivity in MDA-MB 231 cells. Finally, AhR and AKR1C3 expression were positively correlated in human breast cancer. Taken together, our results suggested that AhR is involved in DOX sensitivity by regulating AKR1C3 expression in TNBC cells.


Asunto(s)
Miembro C3 de la Familia 1 de las Aldo-Ceto Reductasas/genética , Doxorrubicina/farmacología , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Receptores de Hidrocarburo de Aril/genética , Neoplasias de la Mama Triple Negativas/genética , Miembro C3 de la Familia 1 de las Aldo-Ceto Reductasas/metabolismo , Animales , Antibióticos Antineoplásicos/farmacología , Apoptosis/efectos de los fármacos , Apoptosis/genética , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Proliferación Celular/genética , Supervivencia Celular/efectos de los fármacos , Supervivencia Celular/genética , Femenino , Técnicas de Inactivación de Genes , Humanos , Receptores de Hidrocarburo de Aril/metabolismo , Neoplasias de la Mama Triple Negativas/tratamiento farmacológico , Neoplasias de la Mama Triple Negativas/metabolismo
4.
Clin Chim Acta ; 490: 69-76, 2019 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-30550937

RESUMEN

BACKGROUND: The levels of plasma sLR11, released from intimal SMCs, are positively associated with intima-media thickness (IMT) in asymptomatic subjects. We have evaluated the yet unknown pathological significance of sLR11 for plaque conditions in patients with carotid artery stenosis. METHODS: The presence of LR11 in carotid plaques was investigated using autopsy specimens. A clinical ultrasonography study for elucidating relationships between sLR11 and plaque condition was performed in 46 patients. RESULTS: Immunohistochemistry showed high levels of LR11 in SMCs within thickened intima and at the media-intima border of atherosclerotic carotid plaques. The levels of sLR11 in patients were clearly elevated compared to healthy controls. Univariate analysis of sLR11 revealed significant positive correlation with plaque score and a tendency to correlate with the stenotic fraction. Univariate and multiple regression analyses of plaque scores showed that sLR11, maximum IMT, and HDL-cholesterol independently determined plaque score. Finally, univariate analysis of initial sLR11 levels for changes in imaging markers after one-year follow-up showed that initial sLR11 levels significantly correlated with stenotic fraction progression. CONCLUSIONS: The levels of sLR11, abundantly expressed in carotid atherosclerotic plaques, are highly associated with increased plaque score. sLR11 levels may be predictive of plaque conditions in patients with advanced carotid atherosclerosis.


Asunto(s)
Estenosis Carotídea/complicaciones , Movimiento Celular , Proteínas Relacionadas con Receptor de LDL/sangre , Proteínas Relacionadas con Receptor de LDL/química , Proteínas de Transporte de Membrana/sangre , Proteínas de Transporte de Membrana/química , Miocitos del Músculo Liso/patología , Placa Aterosclerótica/sangre , Placa Aterosclerótica/complicaciones , Anciano de 80 o más Años , Diferenciación Celular , Femenino , Humanos , Masculino , Placa Aterosclerótica/patología
5.
J Healthc Eng ; 2018: 8961781, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30034677

RESUMEN

Deep learning using convolutional neural networks (CNNs) is a distinguished tool for many image classification tasks. Due to its outstanding robustness and generalization, it is also expected to play a key role to facilitate advanced computer-aided diagnosis (CAD) for pathology images. However, the shortage of well-annotated pathology image data for training deep neural networks has become a major issue at present because of the high-cost annotation upon pathologist's professional observation. Faced with this problem, transfer learning techniques are generally used to reinforcing the capacity of deep neural networks. In order to further boost the performance of the state-of-the-art deep neural networks and alleviate insufficiency of well-annotated data, this paper presents a novel stepwise fine-tuning-based deep learning scheme for gastric pathology image classification and establishes a new type of target-correlative intermediate datasets. Our proposed scheme is deemed capable of making the deep neural network imitating the pathologist's perception manner and of acquiring pathology-related knowledge in advance, but with very limited extra cost in data annotation. The experiments are conducted with both well-annotated gastric pathology data and the proposed target-correlative intermediate data on several state-of-the-art deep neural networks. The results congruously demonstrate the feasibility and superiority of our proposed scheme for boosting the classification performance.


Asunto(s)
Interpretación de Imagen Asistida por Computador/métodos , Redes Neurales de la Computación , Estómago , Algoritmos , Histocitoquímica , Humanos , Estómago/diagnóstico por imagen , Estómago/patología , Neoplasias Gástricas/diagnóstico por imagen , Neoplasias Gástricas/patología
6.
Exp Cell Res ; 366(1): 34-40, 2018 05 01.
Artículo en Inglés | MEDLINE | ID: mdl-29501698

RESUMEN

HER2 overexpression accounts for approximately 15-20% of all breast cancers. We have shown that HER2 overexpression leads to elevated expression of the aryl hydrocarbon receptor (AhR) in breast cancer cells. In this study, firstly, we showed that AhR expression was up-regulated by treatment with the HER3 ligand heregulin (HRG) in HER2-overexpressing breast cancer cell lines. Induction of AhR was mediated by transcriptional activation of the region of AhR promoter corresponding to - 190 to - 100 bp. In addition, HRG treatment elicited nuclear translocation of AhR. To investigate the role of AhR in HRG-HER2/HER3 signaling in HER2-overexpressing cells, we established AhR knockout (KO) HER2-overexpressing cells to perform wound-healing assays. HRG-induced cell migration was markedly attenuated by AhR KO. HRG-induced cell migration was associated with increased expression of the inflammatory cytokines interleukin (IL)-6 and IL-8 in wild type cells, but not in AhR KO cells. These results elucidate that AhR is an important factor for the malignancy in HER2 overexpressing breast cancers.


Asunto(s)
Neoplasias de la Mama/genética , Movimiento Celular/genética , Neurregulina-1/genética , Receptor ErbB-2/genética , Receptores de Hidrocarburo de Aril/genética , Línea Celular Tumoral , Núcleo Celular/genética , Femenino , Humanos , Interleucina-6/genética , Interleucina-8/genética , Regiones Promotoras Genéticas/genética , Receptor ErbB-3/genética , Transducción de Señal/genética , Regulación hacia Arriba/genética , Cicatrización de Heridas/genética
7.
Clin Chim Acta ; 457: 130-6, 2016 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-27079357

RESUMEN

BACKGROUND: The utility of molecules derived from cancer cells as biomarkers of the pathological status in biliary tract and pancreatic cancers is still limited. Soluble LDL receptor relative with 11 ligand-binding repeats (sLR11), a molecule released from immature cells, has been shown to be a circulating biomarker for early stage hematological malignancies. METHODS: We have evaluated the pathological significance of bile sLR11 levels in 147 samples from 72 patients with biliary tract cancer (BTC), pancreatic cancer (PC), or benign diseases. RESULTS: The bile sLR11 levels in the cancer patients were significantly increased compared with those in patients without cancer, independent of cytological detection of cancer cells in bile. The average bile sLR11 levels in cancer patients were significantly higher than in those with benign diseases, while levels of bile carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) were not different. LR11 protein was found to be highly expressed in the BTC and PC cells. The LR11 transcript levels in cholangiocarcinoma and pancreatic cancer cell lines were sharply induced during proliferation and significantly increased under hypoxic conditions. CONCLUSIONS: Therefore, sLR11 levels in bile may be indicative of cancer cell conditions and may serve as potential novel biomarker in patients with BTC and PC.


Asunto(s)
Bilis/metabolismo , Neoplasias del Sistema Biliar/metabolismo , Proteínas Relacionadas con Receptor de LDL/metabolismo , Proteínas de Transporte de Membrana/metabolismo , Neoplasias Pancreáticas/metabolismo , Neoplasias del Sistema Biliar/patología , Antígeno CA-19-9/metabolismo , Antígeno Carcinoembrionario/metabolismo , Línea Celular Tumoral , Proliferación Celular , Humanos , Neoplasias Pancreáticas/patología
8.
Clin Chim Acta ; 452: 167-72, 2016 Jan 15.
Artículo en Inglés | MEDLINE | ID: mdl-26616730

RESUMEN

Tangier disease, characterized by low or absent high-density lipoprotein (HDL), is a rare hereditary lipid storage disorder associated with frequent, but not obligatory, severe premature atherosclerosis due to disturbed reverse cholesterol transport from tissues. The reasons for the heterogeneity in atherogenicity in certain dyslipidemias have not been fully elucidated. Here, using high-performance liquid chromatography with a gel filtration column (HPLC-GFC), we have studied the lipoprotein profile of a 17-year old male patient with Tangier disease who to date has not developed manifest coronary atherosclerosis. The patient was shown to be homozygous for a novel mutation (Leu1097Pro) in the central cytoplasmic region of ATP-binding cassette transporter A1 (ABCA1). Serum total and HDL-cholesterol levels were 59mg/dl and 2mg/dl, respectively. Lipoprotein electrophoretic analyses on agarose and polyacrylamide gels showed the presence of massively abnormal lipoproteins. Further analysis by HPLC-GFC identified significant amounts of lipoproteins in low-density lipoprotein (LDL) subfractions. The lipoprotein particles found in the peak subfraction were smaller than normal LDL, were rich in triglycerides, but poor in cholesterol and phospholipids. These findings in an adolescent Tangier patient suggest that patients in whom these triglyceride-rich, cholesterol- and phospholipid-poor LDL-type particles accumulate over time, would experience an increased propensity for developing atherosclerosis.


Asunto(s)
Transportador 1 de Casete de Unión a ATP/genética , Lipoproteínas/sangre , Enfermedad de Tangier/sangre , Enfermedad de Tangier/genética , Adolescente , Cromatografía en Gel , Cromatografía Líquida de Alta Presión , Humanos , Masculino , Mutación
9.
Biomed Rep ; 1(2): 193-196, 2013 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-24648917

RESUMEN

It is well-known that gene expression levels should be normalized to a carefully selected and appropriately stable internal control gene. However, numerous studies have demonstrated that the expression of housekeeping (HK) genes, typically used as internal control genes varies considerably. A number of studies have shown that ß-2 microglobulin (B2M), an HK gene, frequently used as an internal reference gene, is expressed at low levels in colorectal cancer tissue, when assessed using real-time reverse transcriptase-polymerase chain reaction (RT-PCR). Due to the fact that the expression levels of various HK genes vary depending on the tissue type or experimental conditions, it has been suggested that several control genes should be analyzed in parallel for certain tissues. In the present study, mRNA expression levels of toll-like receptors 2 (TLR2) and 4 (TLR4) in sporadic human colorectal cancerous and non-cancerous tissues were analyzed relative to three HK genes, ß-glucuronidase (GUS), ß-actin (BA) and B2M, using a commercially available tool. Relative expression levels were quantified using the three genes individually and together, and TLR2 as well as TLR4 expression was compared in cancerous and non-cancerous colorectal tissue specimens. Consistent data were obtained in most cases when GUS and BA were used as internal control genes. When B2M was used as the internal control gene, TLR2 and TLR4 expression was demonstrated to be higher in cancerous compared to non-cancerous colorectal tissues. These results were consistent with previous observations of low-level B2M expression in cancerous colorectal tissue and suggest that B2M may be inappropriate as an internal control gene for gene expression studies of colorectal cancer.

10.
Biochem Biophys Res Commun ; 420(4): 901-6, 2012 Apr 20.
Artículo en Inglés | MEDLINE | ID: mdl-22475485

RESUMEN

The human glycine-N-acyltransferase (hGLYAT) gene and two related-genes (GLYATL1 and GLYATL2) were isolated. Human GLYAT, GLYATL1, and GLYATL2 cDNAs were isolated and shown to encode polypeptides of 295, 302, and 294 amino acids, respectively. GLYAT catalyzes glycine-N-acyltransfer reaction with benzoyl-CoA acting as a typical aralkyl transferase, while GLYATL1 catalyzed glutamine-N-acyltransfer reaction with phenylacetyl-CoA as an arylacetyl transferase. GLYAT was shown to be expressed specifically in the liver and kidney, and the cellular localization of GLYAT protein was restricted to the mitochondria. Interestingly, labeling using highly affinity purified anti-GLYAT antibody revealed that GLYAT expression was suppressed in all hepatocellular carcinomas, but not in other liver diseases. hGLYAT repression in cancerous cells in the liver was controlled at the transcriptional level. hGLYAT is a good candidate as a novel marker of hepatocellular carcinoma and may be a key molecule in the transition between differentiation and carcinogenesis of liver cells.


Asunto(s)
Aciltransferasas/antagonistas & inhibidores , Aciltransferasas/metabolismo , Carcinoma Hepatocelular/enzimología , Neoplasias Hepáticas/enzimología , Acilcoenzima A/metabolismo , Aciltransferasas/genética , Secuencia de Aminoácidos , Carcinoma Hepatocelular/genética , Carcinoma Hepatocelular/patología , Línea Celular Tumoral , Humanos , Neoplasias Hepáticas/genética , Neoplasias Hepáticas/patología , Mitocondrias Hepáticas/enzimología , Datos de Secuencia Molecular
11.
Metabolism ; 61(10): 1452-60, 2012 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-22520230

RESUMEN

Pravastatin and atorvastatin increase the serum level of lipoprotein lipase (LPL) mass in vivo but do not increase LPL activity in 3T3-L1 preadipocytes in vitro. LPL is mainly produced by adipose tissue and skeletal muscle cells. Metformin enhances LPL in skeletal muscle through adenosine monophosphate-activated protein kinase (AMPK) activation but not in adipocytes. This study aimed to examine the effect of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) on LPL production and to investigate the mechanism by which statins enhance skeletal muscle cell LPL production. L6 skeletal muscle cells were incubated with pravastatin, simvastatin, atorvastatin or pitavastatin. LPL activity, protein levels and mRNA expression were measured. Atorvastatin and pitavastatin significantly increased LPL activity, protein levels and mRNA expression in L6 skeletal muscle cells at 1 µmol/L, but neither statin had an effect at 10 µmol/L. We measured AMPK to clarify the mechanism by which statins increase LPL production in skeletal muscle cells. At 1 µmol/L, both atorvastatin and pitavastatin enhanced AMPK activity, but this enhancement was abolished when AMPK signaling was blocked by compound C. The increased expressions of LPL protein and mRNA by atorvastatin and pitavastatin were reduced by compound C. In addition, mevalonic acid abolished atorvastatin- and pitavastatin-induced AMPK activation and LPL expression. These results suggest that atorvastatin and pitavastatin increase LPL activity, protein levels and LPL mRNA expression by activating AMPK in skeletal muscle cells.


Asunto(s)
Proteínas Quinasas Activadas por AMP/fisiología , Ácidos Heptanoicos/farmacología , Inhibidores de Hidroximetilglutaril-CoA Reductasas/farmacología , Lipoproteína Lipasa/biosíntesis , Músculo Esquelético/metabolismo , Pirroles/farmacología , Quinolinas/farmacología , Animales , Atorvastatina , Células Cultivadas , Lipoproteína Lipasa/análisis , Lipoproteína Lipasa/genética , Ácido Mevalónico/farmacología , ARN Mensajero/análisis , Ratas , Reacción en Cadena en Tiempo Real de la Polimerasa
12.
Cancer Immunol Immunother ; 61(1): 71-7, 2012 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-21845432

RESUMEN

BACKGROUND: Toll-like receptors (TLRs) play an important role in innate immunity by sensing a variety of pathogens and inducing acquired immunity. To test our hypothesis that dysregulation of innate immune responses acts to trigger carcinogenesis, we studied the expression of TLR2 and 4 in sporadic human colorectal cancer tissue. METHODS: In specimens of cancerous and noncancerous colorectal tissue obtained at surgery, mRNA expression levels of TLR2 and 4 were quantified by TaqMan real-time polymerase chain reaction and compared between the two types of tissue. To confirm TLR2 and TLR4 protein expression levels, immunohistochemical analysis was performed using the same samples. RESULTS: TLR2 mRNA expression was significantly higher in cancerous tissue than in noncancerous tissue, while TLR4 mRNA expression did not differ significantly. Immunohistochemical analysis revealed stronger staining for TLR2 in cancerous mucosal epithelial cells than in noncancerous tissue. Staining for TLR4 in the lamina propria of the mucosa was equally weakly positive in noncancerous tissue and cancerous tissue. This TLR-specific difference in expression suggested that such expression does not only reflect a local inflammatory response to cancer infiltration, i.e., if this was the case, both TLR2 and 4 expression would probably be up-regulated. Our results suggest that TLR2 expression might be involved in sporadic colorectal carcinogenesis, whereas TLR4 is not.


Asunto(s)
Neoplasias Colorrectales/inmunología , Receptor Toll-Like 2/inmunología , Receptor Toll-Like 4/inmunología , Anciano , Anciano de 80 o más Años , Neoplasias Colorrectales/genética , Neoplasias Colorrectales/metabolismo , Femenino , Humanos , Inmunidad Innata/inmunología , Masculino , Persona de Mediana Edad , Reacción en Cadena en Tiempo Real de la Polimerasa , Receptor Toll-Like 2/biosíntesis , Receptor Toll-Like 2/genética , Receptor Toll-Like 4/biosíntesis , Receptor Toll-Like 4/genética
13.
Gan To Kagaku Ryoho ; 35(12): 2247-9, 2008 Nov.
Artículo en Japonés | MEDLINE | ID: mdl-19106585

RESUMEN

Toll-like receptors (TLRs) play an essential role in innate immunity by recognizing various pathogens and by activating acquired immunity. Based on the hypothesis that abnormalities of innate immune responses are involved in carcinogenesis, we examined the presence or absence of the expression of Toll-like receptor 4 (TLR4), comprising one of the TLR families, in colorectal cancer tissues. TLR4 expression in cancerous and non-cancerous colorectal tissue specimens obtained at surgery was investigated by reverse-transcription polymerase chain reaction (RT-PCR). Then, TLR4 expression levels were quantified by real-time PCR and compared between the 2 groups. TLR4 expression was significantly higher in non-cancerous tissues than in cancerous tissues. Interestingly, these results suggested that TLR4 expression was up-regulated in non-cancerous tissues or down-regulated in cancerous tissues in patients with colorectal cancer.


Asunto(s)
Neoplasias Colorrectales/genética , Regulación Neoplásica de la Expresión Génica/genética , Receptor Toll-Like 4/genética , Anciano , Regulación hacia Abajo , Femenino , Humanos , Masculino , Persona de Mediana Edad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA